67 related articles for article (PubMed ID: 23665979)
21. [Polypoidal choroidal vasculopathy].
Yuzawa M
Nippon Ganka Gakkai Zasshi; 2012 Mar; 116(3):200-31; discussion 232. PubMed ID: 22568102
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.
Wang Y; Shen M; Cheng J; Sun X; Kaiser PK
J Ophthalmol; 2020; 2020():4924053. PubMed ID: 32855818
[TBL] [Abstract][Full Text] [Related]
23. Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity.
Mori R; Yuzawa M; Akaza E; Haruyama M
Jpn J Ophthalmol; 2013 Jul; 57(4):365-71. PubMed ID: 23665979
[TBL] [Abstract][Full Text] [Related]
24. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.
Mori R; Tanaka K; Yuzawa M
Medicine (Baltimore); 2018 Jun; 97(25):e11188. PubMed ID: 29924037
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal injection of ranibizumab for recovery of macular function in eyes with subfoveal polypoidal choroidal vasculopathy.
Ogino K; Tsujikawa A; Yamashiro K; Ooto S; Oishi A; Nakata I; Miyake M; Yoshimura N
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3771-9. PubMed ID: 23661367
[TBL] [Abstract][Full Text] [Related]
26. Short-term effectiveness of intravitreal bevacizumab vs. ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Baek JS; Lee DW; Kim CG; Kim JW
Korean J Ophthalmol; 2012 Jun; 26(3):157-62. PubMed ID: 22670070
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up.
Matsumiya W; Honda S; Kusuhara S; Tsukahara Y; Negi A
BMC Ophthalmol; 2013 Apr; 13():10. PubMed ID: 23557322
[TBL] [Abstract][Full Text] [Related]
28. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
29. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.
Hikichi T; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H; Ariga H
Am J Ophthalmol; 2012 Jul; 154(1):117-124.e1. PubMed ID: 22465366
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
31. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
[TBL] [Abstract][Full Text] [Related]
32. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.
Akaza E; Yuzawa M; Mori R
Jpn J Ophthalmol; 2011 Jan; 55(1):39-44. PubMed ID: 21331691
[TBL] [Abstract][Full Text] [Related]
33. Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.
Tsujikawa A; Ooto S; Yamashiro K; Tamura H; Otani A; Yoshimura N
Jpn J Ophthalmol; 2010 Jul; 54(4):310-9. PubMed ID: 20700799
[TBL] [Abstract][Full Text] [Related]
34. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.
Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
Am J Ophthalmol; 2010 Nov; 150(5):674-682.e1. PubMed ID: 20691424
[TBL] [Abstract][Full Text] [Related]
35. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
[TBL] [Abstract][Full Text] [Related]
36. One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Yamashita A; Shiraga F; Shiragami C; Ono A; Tenkumo K
Am J Ophthalmol; 2010 Mar; 149(3):465-71.e1. PubMed ID: 20042180
[TBL] [Abstract][Full Text] [Related]
37. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results.
Kokame GT; Yeung L; Lai JC
Br J Ophthalmol; 2010 Mar; 94(3):297-301. PubMed ID: 19726427
[TBL] [Abstract][Full Text] [Related]
38. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials.
Mitchell P; Korobelnik JF; Lanzetta P; Holz FG; Prünte C; Schmidt-Erfurth U; Tano Y; Wolf S
Br J Ophthalmol; 2010 Jan; 94(1):2-13. PubMed ID: 19443462
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
